Unlocking the Value in Your Data


When it comes to accelerating revenue growth and competitive differentiation, data has become an imperative asset for businesses in today’s digital economy. This report by Criticaleye partner Hitachi Solutions explores how organisations can truly unlock the value of their data.

Key takeaways include:

  • For CEOs and CFOs, creating a data-driven culture is essential for enabling the business to become more agile, innovative and focused on data as a strategic asset
  • Without the proper data infrastructure, AI efforts are likely to be ineffective and will fail to deliver expected results
  • Data monetisation is not a one-time initiative, but an ongoing process of unlocking value form data

Share this with your Community





Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

Where M&A Value is Won or Lost

M&A can create significant opportunities for growth, but realising the expected value often depends on how effectively organisations manage the people side of a transaction. This report by LACE Partners explores how...


Click here to download this insight

The Tech Making CPOs Go Faster

As the HR function evolves, technology investment decisions have become a marker of ambition and maturity, not just efficiency. But talk to CPOs at the sharp end of these decisions and a more complicated picture emer...


Jane Pateman, NED at Knights plc: What Changes from CPO to NED?

Moving from CPO to NED means shifting from execution to influence, challenge and oversight. In this episode, Bridgette Hall, Senior Editor at Criticaleye, speaks with Jane Pateman, NED at Knights plc and Critical...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 239




British Land Lightsource bp NatWest Group Mayborn Group Stream AlixPartners E.ON UK LACE Partners Hitachi Solutions London Stock Exchange Group Global Payments NATS Drax Group plc Legal & General Rolls-Royce GlaxoSmithKline plc